Indicate the intravenous anesthetic,which is an ultra-short-acting barbiturate:

Correct Answer: B

Rationale: Step-by-step rationale for choice B: Thiopental: 1. Thiopental is an ultra-short-acting barbiturate commonly used as an intravenous anesthetic. 2. It has a rapid onset of action and short duration of effect, making it ideal for induction of anesthesia. 3. Its pharmacokinetics allow for quick recovery and minimal residual effects. 4. Fentanyl (choice A) is a synthetic opioid, Midazolam (choice C) is a benzodiazepine, and Ketamine (choice D) is a dissociative anesthetic, not barbiturate.

Correct Answer: A

Rationale: Tranexamic acid is structurally similar to aminocaproic acid, making it an analog. This similarity allows tranexamic acid to competitively inhibit the activation of plasminogen to plasmin, effectively reducing fibrinolysis. Therefore, the statement is TRUE. Choices B, C, and D are incorrect because tranexamic acid is indeed an analog of aminocaproic acid, making them mutually exclusive options.

Correct Answer: A

Rationale: The correct answer is A: Skeletal muscle weakness. Calcium channel blockers primarily affect smooth muscle in blood vessels and the heart, not skeletal muscles. Dizziness, headache, and flushing are common adverse effects due to vasodilation and reduced cardiac output. Therefore, the correct answer is A because skeletal muscle weakness is not a typical adverse effect of calcium channel blockers.

Correct Answer: C

Rationale: The correct answer is C: Angiotensin-converting enzyme inhibitors. These drugs inhibit the enzyme that breaks down bradykinin, leading to its accumulation. Ganglioblockers (A) and Alfa-adrenoblockers (B) do not directly affect bradykinin metabolism. Diuretics (D) primarily act on sodium and water balance, not bradykinin metabolism. In summary, C is correct as ACE inhibitors specifically inhibit bradykinin breakdown, while the other choices do not target this mechanism.

Correct Answer: D

Rationale: The correct answer is D because all three dopamine agonists, Bromocriptine, Cabergoline, and Pergolide, are known to decrease pituitary prolactin secretion. Dopamine inhibits prolactin release from the pituitary gland, and these agonists mimic dopamine's action. Therefore, all three choices are correct. Summary: A: Bromocriptine - Decreases pituitary prolactin secretion. B: Cabergoline - Decreases pituitary prolactin secretion. C: Pergolide - Decreases pituitary prolactin secretion. All choices are correct as they are dopamine agonists that decrease pituitary prolactin secretion.